Discovery of SCH446211 (SCH6): A new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication

Journal of Medicinal Chemistry

Volumn 49, Issue 9, 2006, Pages 2750-2757

  Bogen, Stéphane L ^a   Arasappan, Ashok ^a   Bennett, Frank ^a   Chen, Kevin ^a   Jao, Edwin ^a   Liu, Yi Tsung ^a   Lovey, Raymond G ^a   Venkatraman, Srikanth ^a   Pan, Weidong ^a   Parekh, Tajel ^a   Pike, Russel E ^a   Ruan, Sumei ^a   Liu, Rong ^a   Baroudy, Bahige ^a   Agrawal, Sony ^a   Chase, Robert ^a   Ingravallo, Paul ^a   Pichardo, John ^a   Prongay, Andrew ^a   Brisson, Jean Marc ^a   Hsieh, Tony Y ^a   Cheng, Kuo Chi ^a   Kemp, Scott J ^b   Levy, Odile E ^b   Lim Wilby, Marguerita ^b   Tamura, Susan Y ^b   Saksena, Anil K ^a   Girijavallabhan, Viyyoor ^a   Njoroge, F George ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DIMETHYLETHYL [1 [[2 [[[1 [2 [[2 [[2 (DIMETHYLAMINO) 2 OXO 1 PHENYLETHYL]AMINO] 2 OXOETHYL]AMINO] 1,2 DIOXOETHYL] 4,4,4 TRIFLUOROBUTYL]AMINO]CARBONYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXAN 3 YL]CARBONYL] 2,2 DIMETHYLPROPYL]CARBAMATE; ANTIVIRUS AGENT; INTERFERON REGULATORY FACTOR 3; KETOAMIDE INHIBITOR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 INHIBITOR; PROLINE DERIVATIVE; SCH 446211; SCH 6; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; ENZYME INHIBITION; GENOTYPE; HEPATITIS C VIRUS; IC 50; IC 90; NONHUMAN; PROTEIN BINDING; REPLICON; VIRUS REPLICATION;

AMIDES; ANIMALS; GENOME, VIRAL; HAPLORHINI; HEPACIVIRUS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OLIGOPEPTIDES; RATS; RNA, VIRAL; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33646449468     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060077j     Document Type: Article

References (32)

1. (a) Cohen, J. The Scientific Challenge of Hepatitis C. Science 1999, 285, 26-30.
2. (b) Alter, M. J.; Kruszon-Moran, D.; Nainan, O. V.; McQuillan, G. M.; Gao, F.; Moyer, L. A.; Kaslow, R. A.; Margolis, H. S. The Prevalence of Hepatitis C Virus Infection in The United States, 1988 Through 1994. N. Engl. J. Med. 1999, 341, 556-562.
3. (c) Cuthbert, J. A. Hepatitis C: Progress and Problems. Clin. Microbiol. Rev. 1994, 7, 505-532. 0
4. Narjes, F.; Koch, U.; Steinküler, C. Recent developments in the discovery of hepatitis C virus serine protease inhibitors-towards a new class of antiviral agents. Expert Opin. Investig. Drugs 2003, 12, 153-16
5. (a) Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74, 2046-2051.
6. (b) Bartenschlager, R.; Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81, 1631-48.
7. (a) Steinkuhler, C.; Koch, U.; Narjes, F.; Matassa, V. G. Hepatitis C virus serine protease inhibitors: current progress and future challenges. Curr. Med. Chem. 2001, 8, 919-932.
8. (b) Kwong, A. D.; Kim, J. L.; Rao, G.; Lipovsek, D.; Raybuck, S. A. Hepatitis C virus NS3/4A protease. Antiviral Res. 1998, 40, 1-18.
9. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A. M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M. A.; Rancourt, J.; Sentjens, R. E.; St George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C. L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426, 314.
10. Reesink, H. W.; Zeuzem, S.; Weegink, C. J.; Forestier, N.; van Vliet, A.; van de Wetering deRooij, J.; McNair, L.; Purdy, S.; Chu, H.-M.; Jasen, P. L. M. In 36th Digestive Disease Week, 2005, Chicago, IL.
11. Arasappan, A.; Njoroge, F. G.; Parekh, T. N.; Yang, X.; Pichardo, J.; Butkiewicz, N.; Prongay, A.; Yao, N.; Girijavallabhan, V. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as Hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex. Bioorg. Med. Chem. Lett. 2004, 14, 5751-5755
12. (a) Bennett, J. M.; Campbell, A. D.; Campbell, A. J.; Carr, M. G.; Dunsdon, R. M.; Greening, J. R.; Hurst, D. N.; Jennings, N. S.; Jones, P. S.; Jordan, S.; Kay, P. B.; O'Brien, M. A.; King-Underwood, J.; Raynham, T. M.; Wilkinson, C. S.; Wilkinson, T. C. I.; Wilson, F. X. The identification of α-ketoamides as potent inhibitors of hepatitis c virus NS3-4A proteinase. Bioorg. Med. Chem. Lett. 2001, 11, 355-357.
13. (b) Han, W.; Hu, Z.; Jiang, X.; Decicco, C. P. α-Keto amides, a-keto esters, and α-diketones as HCV NS3 protease inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 711-713.
14. Arasappan, A.; Njoroge, F. G.; Chan, T. Y.; Bennett, F.; Bogen, S.; Chen, K.; Gu, H.; Hong, L.; Jao, E.; Liu, Y.-T.; Lovey, R. G.; Parekh, T.; Pike, R. E.; Pinto, P.; Santhanam, S.; Venkatraman, V.; Vaccaro, H.; Wang, H.; Yang, X.; Zhu, B.; Mckittrick, B.; Saksena, A. K.; Girijavallabhan, V.; Pichardo, J.; Butkiewicz, N.; Ingram, R.; Malcolm, B.; Prongay, A.; Yao, N.; Marten, B.; Madison, V.; Kemp, S.; Levy, O.; Lim-Wilby, M.; Tamura, S.; Ganguly, A. K. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P′2 moiety with improved potency. Bioorg. Med. Chem. Lett. 2005, 15, 4180-4184.
15. 2′ α-ketoamide inhibitors of HCV NS3-4A serine protease: Effect on HCV replicon activity. Bioorg. Med. Chem. Lett. 2005, 16, 1621-1627.
16. Boc-protected α-hydroxyacid were prepared via modification of the following procedures. (a) Chen, K.; Njoroge, F. G.; Pichardo, J.; Prongay, A.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Design, Synthesis and Biological Activity of m-Tyrosine-Based 16- and 17-Membered Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease. J. Med. Chem. 2005, 48, 6229-6235.
17. (b) Chen, M.; Green, M. D.; Zhang, F. Process and intermediates for the preparation of 3-amino-3-(cyclobutylmethyl)-2-hydroxypropionamide or its salts. WO 2004113272.
18. (a) Del Valle, J. R.; Goodman, M. Asymmetric Hydrogenations for the Synthesis of Boc-Protected 4-Alkylprolinols and Prolines. J. Org. Chem. 2003, 68, 3923-3931.
19. (b) Ezquerra, J.; Pedregal, C.; Rubio, A.; Vaquero, J. J.; Matia, M. P.; Martin, J.; Diaz, A.; Navio, J. L. G.; Deeter, J. B. Stereoselective Double Alkylation of Ethyl N-Bocpyroglutamate. J. Org. Chem. 1994, 59, 4327-4331.
20. (c) Smith, E. M.; Swiss, G. F.; Neustadt, B. R.; Gold, E. H.; Sommer, J. A.; Brown, A. D.; Chiu, P. J. S.; Moran, R.; Sybertz, E. J.; Baum, T. Synthesis and pharmacological activity of angiotensin-converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines. J. Med. Chem. 1988, 31, 875-885.
21. (d) Liu, Y. T.; Wong, J. K.; Tao, M.; Osterman, R.; Sannigrahi, M.; Girijavallabhan, V. M.; Saksena, A. Carboxy mediated stereoselective reduction of ketones with sodium triacetoxyborohydride: synthesis of novel 3,4-fused tetrahydropyran and tetrahydrofuran prolines. Tetrahedron Lett. 2004, 45, 6097-6100.
22. (e) Jao, E.; Bogen, S.; Saksena, A. K.; Girijavallabhan, V. [3+2] Cycloaddition of trimethylenemethane (TMM) to α,β-unsaturated γ-lactam. Preparation of 5,5-fused proline surrogates. Tetrahedron Lett. 2003, 44, 5033-5035.
23. (f) Zhang, R.; Mamai, A.; Madalengoitia, J. S. Cyclopropanation Reactions of Pyroglutamic Acid-Derived Synthons with Alkylidene Transfer Reagents. J. Org. Chem. 1999, 64, 547-555.
24. Dess, D. B.; Martin, J. C. A Useful Triacetoxyperiodinane for the Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related Species. J. Am. Chem. Soc. 1991, 113, 7277-7287.
25. Pfitzner, K. E.; Moffatt, J. G. New and selective oxidation of alcohols. J. Am. Chem. Soc. 1963, 85, 3027-3028.
26. Zhang, R.; Beyer, B. M.; Durkin, J.; Ingram, R.; Njoroge, F. G.; Windsor, W. T.; Malcolm, B. A. A Continuous Spectrophotometric Assay for the Hepatitis C Virus Serine Protease. Anal. Biochem. 1999, 270, 268-275. The substrate Ac-DTEDVVP(Nva)-O-PAP was used in the present study.
27. Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
28. 1 cyclopropyl alanine combination for improved potency. Bioorg. Med. Chem. Lett. 2005, 15, 4515-4519.
29. Mamai, A.; Zhang, R.; Natarajan, A.; Madalengoitia, J. S. Poly-L-proline Type II Peptide Mimics Based on the 3-Azabicyclo[3.1.0]-hexane System. J. Org. Chem. 2001, 66, 455-460.
30. Liu, R.; Abid, K.; Pichardo, J.; Pazienza, V.; Ingravallo, P.; Kong, R.; Agrawal, S.; Bogen, S.; Saksena, A.; Prongay, A.; Njoroge, F. G.; Baroudy, B. M.; Negro, F. In Vitro Antiviral Activity of Sch 446211 (SCH6), a Novel Inhibitor of the Hepatitis C Virus NS3 Serine Protease. J. Hepatol. 2005, submitted for publication.
31. Rice, C. M.; Lindenbach, B. D.; Evans, M. J.; Syder, A. J.; Wölk, B.; Tellinghuisen, T. L.; Liu, C. C.; Maruyama, T.; Hynes, R. O.; Burton, D. R.; McKeating, J. Complete Replication of Hepatitis C Virus in Cell Culture. A. Science 2005, 309, 623-626.
32. Foy, E.; Li, K.; Wang, C.; Sumpter, R., Jr.; Ikeda, M.; Lemon, S. M.; Gale, M. J. Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease. Science 2003, 300, 1145-1148.